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Methods

Inclusion and exclusion criteria
Ambulant community-dwelling men and women aged 65 years and older were identified from a single general practice in Oxfordshire and mailed an invitation letter to participate in the trial. The invitation letter included a screening questionnaire to check eligibility and a study information leaflet. Those who returned the screening questionnaire and were potentially eligible were provided with an appointment for a randomization study visit. People were ineligible if they were: nursing home residents; regular users of vitamin D supplements more than 10 µg (400 IU) vitamin D daily; prescribed calcium supplements, bisphosphonates, parathyroid hormone (PTH), or calcitonin; had medically diagnosed dementia or history of hypercalcaemia, hyperparathyroidism lymphoma, sarcoidosis, active tuberculosis or renal calculus; were judged by their doctor as likely to be poorly compliant with clinic visits or medication; or had a history of alcohol or substance misuse or a history that might limit their ability to take the study treatment (e.g. terminal illness). All participants provided written informed consent. Analysis Plan is provided in the Web-Appendix). Allowance will be made in their interpretation for multiple hypothesis testing (taking into account, if relevant, the type of measure and evidence from other studies) (22, 23) . But, the more extreme the pvalue (or, analogously, the further the confidence interval is from zero) after any allowance has been made for the nature of the particular comparison, the more reliable the comparison and, hence, the more definite any finding will be considered. Table 1 shows a summary of the study procedures. Study visits were conducted by trained study nurses at the participant's home (but the final visit also included an additional visit to the General Practice: see below). At the first visit (month 0), eligibility was assessed and relevant medical history and medication, calcium intake, and baseline measures recorded. If willing and eligible, participants were randomized in a ratio of 1:1:1 to vitamin D3 100 µg (4000 IU), vitamin D3 50 µg 
Outcomes
Randomization and blinding
Post-randomization follow-up
About 100 participants were randomly selected for a blood sample at 1 month (Table   1 ). All participants were to have follow-up visits from the study nurse at 6 and 12 months (Table 1) . Compliance and adverse events were evaluated at each visit along with selected tests. Depression scores were assessed at 6 and 12 months using a 4-point Geriatric Depression Score (24) . Spot urine samples were collected at the final home visit. Participants were invited to attend a special clinic at their local General Practice for a bone scan to assess heel and wrist bone density and a short physical performance battery (25) 
Safety
At each visit non-serious adverse events (NSAEs) thought related to the study treatment or that resulted in the participant stopping treatment, and all serious adverse events (SAEs) were recorded in the electronic case report forms.
Participants were provided with a 24-hour Freefone number to contact a clinician at CTSU should they wish to discuss trial-related medical problems.
Cardiovascular assessments
At each visit blood pressure and arterial stiffness were measured after 10 minutes of rest in the seated position (26) . A finger probe (Pulsetrace PCA 2) placed on the right forefinger recorded the 'digital volume pulse' using photoplethysmography over 30-60 seconds. This was followed by blood pressure and brachial artery arterial stiffness measurements made over 2 minutes using a TensioClinicTM® arteriograph.
Left ventricular function was assessed by echocardiography in a randomly selected subset of 151 participants at the final visit (who provided separate consent for this examination). Any significant abnormalities were to be reported to the participant's GP.
Musculoskeletal parameters
A history of falls in the last 6 months and fractures at any time was recorded at randomization, 6 and 12 months. Participants were asked to rate from 1 to 10 their Page 12 of 23 A c c e p t e d M a n u s c r i p t 12 level of physical activity, and the presence and severity of any muscle and, separately, joint pain, if present. Hand grip strength was assessed using a Jamar TM J00105 hydraulic dynamometer, as previously described (27) . A modified short physical performance battery at the final visit evaluated the time taken for five consecutive chair rises, the time to walk 3 metres, and a balance score calculated from the time that balance was held in the tandem, semi-tandem, and side-by-side stances (25) . Heel and wrist bone mineral density were measured using an OsteoSys EXA-3000 scanner (OsteoSYS, Seoul, Korea).
Laboratory analyses
Blood samples were collected at each visit into 2 standard 10 ml tubes (one containing EDTA and one lithium heparin) and at baseline and 12 months also into a 
Results
Characteristics of study participants
From the registered patients at the practice in this age group, 932 were invited to participate, 313 (33%) agreed to have a randomization visit from the study nurse and had their bone density measured and 151 had cardiac echocardiography.
Baseline characteristics
Among the 305 participants, the overall mean age was 72 (SD 6) years, 51% were men, 14% had a prior history of IHD, 6% had stroke/TIA, 9% had diabetes and 39% had hypertension. Overall, 30% had any prior history of fracture and 13% had a history of a fall in the last 6 months. Table 2 Plasma biochemistry measurements at 1 month will be analyzed in a sub-set of 100 participants. M a n u s c r i p t 
